liiseann
pirofski
arturo
casadeval
spectrum
infecti
diseas
shift
past
year
includ
caus
microb
caus
diseas
predominantli
immunocompromis
individu
phenomenon
underscor
depend
microbi
virul
immun
statu
host
limit
efficaci
avail
antimicrobi
armamentarium
immunocompromis
individu
combin
increas
resist
agent
led
urgent
need
new
therapi
infecti
diseas
immunomodul
repres
novel
approach
antimicrobi
therapi
depend
bolster
host
immun
rather
direct
antimicrobi
activ
immunomodul
divid
specif
pathogen
pathogenspecif
specif
pathogen
nonspecif
howev
date
immunomodul
evalu
efficaci
antimicrobi
tool
introduct
immunomodul
context
damagerespons
framework
immunomodul
usual
product
immun
system
use
consid
immunomodul
approach
infecti
diseas
context
microbi
pathogenesi
contrast
microbecentr
view
microbi
pathogenesi
virul
consid
reflect
singular
microbi
function
damagerespons
framework
provid
flexibl
construct
account
contribut
host
well
microb
entiti
damagerespons
framework
consid
host
damag
common
denomin
microbi
pathogenesi
base
tenet
host
damag
plot
host
immun
respons
ushap
curv
wherebi
maxim
host
damag
result
given
hostmicrob
interact
occur
immun
respons
weak
overli
strong
figur
inher
flexibl
afford
curv
lie
abil
account
fact
certain
microb
caus
diseas
certain
host
phenomenon
explain
view
microbi
pathogenesi
consid
virul
singular
microbi
trait
logic
corollari
damagerespons
framework
infecti
diseas
occur
suscept
host
host
immun
mechan
protect
infecti
diseas
prevent
reduc
damag
result
hostmicrob
interact
relationship
host
immun
microbi
pathogenesi
clearli
exemplifi
immunocompromis
host
diseas
caus
commens
microb
candida
albican
staphylococcu
epidermidi
fungi
cryptococcu
neoforman
pneumocysti
jurevecci
success
immun
reconstitut
prevent
hivassoci
diseas
caus
microb
phenomenon
immun
reconstitut
diseas
follow
antiretrovir
therapi
highli
activ
antiretrovir
therapi
haart
patient
aid
acquir
immunodefici
syndrom
illustr
rebound
immun
produc
diseas
discuss
success
antimicrobi
therapi
function
abil
amelior
diseas
diseas
manifest
host
damag
damagerespons
framework
provid
use
construct
consid
approach
treat
infecti
diseas
reduc
host
damag
result
hostmicrob
interact
crisi
antimicrobi
therapi
stem
antibiot
overus
misus
limit
number
new
antimicrobi
drug
near
horizon
well
document
howev
anoth
area
limit
util
antimicrobi
drugbas
therapi
antimicrobi
agent
frequent
ineffect
individu
impair
immun
often
despit
highli
activ
vitro
individu
intact
immun
underscor
crucial
relationship
host
immun
microbi
virul
provid
power
rational
approach
antimicrobi
therapi
regul
immun
respons
reduc
amelior
prevent
host
damag
approach
immunomodul
divid
specif
pathogen
pathogenspecif
nonspecif
pathogenspecif
immunomodul
includ
antibodi
reagent
vaccin
except
rabi
varicellazost
vaccin
current
licens
vaccin
administ
prevent
acut
infecti
diseas
rather
therapi
discuss
nonspecif
immunomodul
includ
cytokin
antimicrobi
peptid
certain
antimicrobi
drug
microb
probiot
present
clinic
experi
nonspecif
immunomodul
antimicrobi
tool
predominantli
limit
cytokin
power
histor
preced
use
antibodybas
therapi
treat
infecti
diseas
review
first
era
antimicrobi
therapi
earli
centuri
base
serum
therapi
antibodi
prepar
henc
inaugur
antimicrobi
agent
immunomodul
first
gener
antibodi
reagent
abandon
toxic
result
impur
deriv
nonhuman
speci
arriv
antimicrobi
drug
act
directli
microb
nonetheless
evid
synerg
antibiot
serum
therapi
serum
therapi
valid
anim
model
administ
human
howev
mechan
amelior
infecti
diseas
enhanc
efficaci
antimicrobi
drug
larg
unknown
centuri
mechan
antibodi
action
thought
influenc
antibodi
efficaci
includ
abil
neutral
promot
opson
possibl
effect
ifng
therapi
two
patient
cryptococcosi
context
damagerespons
framework
patient
individu
aidsrel
cryptococcosi
suscept
infect
associ
profound
defect
immun
result
tcell
defici
patient
administr
ifng
proinflammatori
increas
inflammatori
respons
might
facilit
control
infect
thu
reduc
damag
symptom
diseas
contrast
patient
individu
cryptococc
diseas
follow
immun
reconstitut
haart
patient
administr
ifng
might
detriment
cryptococc
diseas
caus
exuber
inflammatori
respons
henc
outcom
ifng
therapi
depend
immun
statu
host
illustr
dichotom
requir
immunomodul
patient
differ
immun
statu
patient
infecti
diseas
reflect
outcom
weak
immun
respons
hivassoci
histoplasmosi
aspergillosi
follow
stem
cell
transplant
individu
enhanc
inflammatori
respons
proinflammatori
immunomodul
could
facilit
microbi
clearanc
thu
reduc
damag
symptom
diseas
contrast
patient
infecti
diseas
reflect
outcom
overli
exuber
immun
respons
mediastin
fibrosi
histoplasmosi
allerg
aspergillosi
individu
antiinflammatori
immunomodul
could
dampen
host
inflammatori
respons
thu
reduc
damag
symptom
diseas
notabl
immun
respons
individu
could
alreadi
result
microbi
clearanc
patient
illustr
kind
immunomodul
would
benefici
probabl
influenc
immun
statu
affect
individu
phagocytosi
antibodydepend
cellmedi
cytotox
adcc
andor
activ
complement
howev
significantli
robust
menu
potenti
mechan
antibodi
action
includ
direct
antimicrobi
action
immunomodul
gener
oxid
speci
emerg
past
decad
exampl
efficaci
pneumococc
capsular
polysaccharidespecif
antibodi
associ
modul
cellular
respons
pneumococcu
lung
mice
pulmonari
infect
find
suggest
welldocu
abil
serum
therapi
amelior
fever
clinic
symptom
pneumococc
pneumonia
could
reflect
downregul
host
inflammatori
respons
damag
control
perhap
observ
pneumococc
pneumonia
respons
serum
therapi
homolog
capsular
polysaccharidesspecif
antiserum
first
three
day
symptom
indic
capac
mediat
immunomodul
limit
earli
stage
diseas
antibodi
microb
includ
c
neoforman
histoplasma
capsulatum
abl
modul
cellular
immun
respons
pulmonari
infect
see
studi
antibodi
action
shown
older
dichotom
view
antibodi
immun
effect
extracellular
pathogen
wherea
cellular
immun
respons
immun
intracellular
pathogen
deconstruct
evid
antibodi
reagent
effect
classic
intracellular
pathogen
mycobacterium
tuberculosi
c
neoforman
h
capsulatum
score
virus
current
one
antibodi
reagent
licens
use
infecti
diseas
unit
state
palivizumab
licens
palivizumab
neutral
human
monoclon
antibodi
mab
protein
f
respiratori
syncyti
viru
rsv
reduc
hospit
rsv
prematur
highrisk
infant
given
prophylaxi
antivir
activ
palivizumab
associ
reduct
inflammatori
mediat
releas
murin
model
rsv
mechan
action
probabl
involv
immunomodul
despit
ongo
controversi
cost
target
popul
palivizumab
success
reduc
risk
rsv
highrisk
infant
promot
develop
second
gener
reagent
vaccin
candid
recent
mycograb
human
recombin
antibodi
fragment
shown
significantli
improv
respons
amphotericin
b
patient
invas
candidiasi
patient
receiv
mycograb
amphotericin
b
show
higher
rate
complet
overal
respons
day
therapi
significantli
better
mycolog
respons
less
candidaattribut
mortal
patient
receiv
amphotericin
b
placebo
mycograb
safe
welltoler
howev
episod
hypertens
occur
frequent
patient
receiv
mycograb
receiv
placebo
mycograb
recombin
antibodi
fragment
lack
fc
region
produc
human
heatshock
protein
cdna
librari
epitop
inhibit
fungal
nilkvirknivkk
develop
antibodi
driven
observ
recoveri
invas
candidiasi
associ
appear
antibodi
kda
determin
found
fungal
homolog
human
mycograb
test
patient
comparison
standard
therapi
question
whether
efficaci
vivo
depend
synergi
antifung
drug
unansw
nonetheless
vitro
activ
mycograb
amphotericin
b
antifung
agent
resist
candida
fungal
speci
suggest
could
hold
promis
broadli
activ
antifung
agent
first
mab
use
treat
fungal
diseas
human
mous
mab
bind
cryptococc
capsular
polysaccharid
glucuronoxylomannan
extens
preclin
test
reveal
augment
host
defens
mechan
c
neoforman
vitro
vivo
review
clinic
trial
administr
singl
mg
kg
dose
hivinfect
patient
treat
cryptococc
mening
welltoler
associ
reduct
serum
glucuronoxylomannan
level
toler
promis
effect
reagent
hivinfect
patient
bolster
prospect
immunotherapeut
intervent
potenti
augment
host
immun
mechan
treatment
infecti
diseas
immunocompromis
individu
mab
develop
myriad
microb
respons
emerg
infecti
diseas
andor
caus
diseas
set
immun
impair
human
mab
bacillu
anthraci
toxin
recent
success
complet
phase
trial
stand
potenti
use
therapeut
event
anthrax
biolog
attack
sever
human
mab
sar
sever
acut
respiratori
syndrom
coronaviru
develop
might
use
diseas
reappear
remark
mab
develop
point
clinic
use
possibl
less
five
year
human
mab
highli
effect
experiment
shigatoxin
produc
escherichia
coli
piglet
studi
experiment
model
reveal
efficaci
certain
mab
depend
intact
cellular
immun
see
use
mab
immunocompromis
patient
could
depend
whether
efficaci
requir
immun
function
subset
element
lack
relev
patient
mab
advantag
homogen
high
specif
activ
although
concern
mab
could
limit
use
microb
demonstr
high
antigen
variat
mutabl
combin
mab
shown
promis
overcom
limit
anoth
type
antibodybas
therapi
infecti
diseas
consist
polyclon
immunoglobulinbas
agent
includ
intraven
immunoglobulin
ivig
specif
immun
globulin
sig
sometim
call
hyperimmun
globulin
treatment
prevent
rabi
depend
entir
combin
two
immunomodul
rabi
vaccin
rabi
immun
globulin
cytokinebas
therapi
contrast
antibodi
reagent
pathogenspecif
rational
use
cytokin
adjunct
immunomodul
infecti
diseas
base
concept
replac
augment
natur
mediat
host
defens
enhanc
antimicrobi
effect
host
immun
mechan
andor
antimicrobi
agent
despit
logic
basi
concept
potenti
antimicrobi
power
agent
difficult
har
clinic
current
exampl
use
adjunct
cytokin
infecti
diseas
notabl
except
use
recombin
ainterferon
nucleosid
analog
hepat
b
viru
hbv
pegyl
interferon
ribavirin
hepat
c
viru
hcv
efficaci
interferon
hcv
attribut
induct
immun
side
effect
interferonbas
therapi
limit
use
certain
patient
depress
effecaci
adjunct
interferongamma
amphotericin
b
studi
phase
ii
doubleblind
placebocontrol
trial
aidsassoci
cryptococc
mening
trend
toward
mycolog
respons
clinic
improv
among
interferon
recipi
show
improv
compar
placebocontrol
subject
although
differ
reach
statist
signific
trend
toward
benefici
effect
adjunct
interferon
encourag
call
larger
scale
studi
studi
identifi
patient
adjunct
immunotherapi
could
benefici
rational
interferon
therapi
cryptococcosi
strong
basi
preclin
studi
mice
human
studi
show
associ
cerebrospin
fluid
level
ifng
treatment
hivinfect
patient
cryptococc
mening
light
establish
benefit
interferon
therapi
prevent
bacteri
diseas
patient
chronic
granulomat
diseas
adjunct
interferon
could
hold
promis
adjunct
agent
hivassoci
cryptococc
mening
howev
absenc
surrog
marker
predict
patient
would
benefit
interferon
therapi
underscor
potenti
pitfal
studydesign
patient
select
clinic
trial
particularli
problemat
cryptococc
mening
diseas
occur
case
weak
reconstitut
immun
patient
hiv
infect
failur
demonstr
effect
proinflammatori
immunomodul
could
reflect
induct
excess
inflammatori
respons
promot
diseas
figur
provid
schemat
interpret
use
ifng
therapi
context
damagerespons
framework
depend
immunolog
statu
affect
patient
adjunct
ifng
therapi
could
benefici
detriment
preclin
data
demonstr
import
helper
tcell
respons
protect
fungi
experiment
model
led
propos
adjunct
cytokin
use
antifung
agent
invas
fungal
infect
rational
use
coloni
stimul
factor
csf
deriv
granulocyt
gcsf
macrophag
gmcsf
part
base
abil
allevi
neutropenia
data
clinic
use
adjunct
csf
fungal
diseas
limit
small
studi
case
report
see
review
nonetheless
administr
gmcsf
antifung
agent
patient
invas
fungal
infect
associ
decreas
patient
mortal
better
respons
rate
compar
placebo
antifung
therapi
alon
view
small
number
affect
patient
medic
ethic
consider
design
random
doubleblind
placebocontrol
studi
possibl
safe
welltoler
candid
immunomodul
benefici
preclin
studi
find
way
antimicrobi
armamentarium
compassion
use
protocol
salvag
therapi
rational
use
adjunct
proinflammatori
cytokin
certain
antibodi
treat
infecti
diseas
enhanc
host
respons
howev
rel
underappreci
principl
microbi
pathogenesi
damag
result
hostmicrob
interact
result
overli
exuber
host
respons
henc
rational
use
therapeut
intervent
dampen
reduc
well
enhanc
augment
inflammatori
respons
propos
benefici
effect
ivig
inflammatori
diseas
involv
engag
inhibitori
fc
receptor
downregul
inflammatori
respons
probiot
live
bacteria
deriv
human
gastrointestin
tract
use
therapi
inflammatori
bowel
diseas
includ
antibioticassoci
diarrhea
probiot
remain
outsid
establish
antimicrobi
armamentarium
fraught
potenti
harm
immunocompromis
host
nonetheless
logic
postul
replac
andor
enhanc
activ
human
microbiota
could
benefici
treatment
infecti
diseas
reflect
failur
mucos
surfac
innat
mechan
bolster
protect
microbemedi
damag
see
abil
macrolid
suppress
releas
inflammatori
mediat
phagocyt
vitro
recogn
time
clinic
relev
phenomenon
remain
uncertain
nonetheless
hypothes
benefit
lowdos
macrolid
therapi
chronic
pulmonari
diseas
could
result
macrolideinduc
reduct
level
inflammatori
cytokin
neutrophil
recruit
biofilm
format
observ
anim
model
andor
vitro
contrast
macrolid
amphotericin
b
penicillin
induc
releas
inflammatori
mediat
vitro
tolllik
receptor
mediat
stimul
inflammatori
properti
drug
rais
question
whether
immunomodulatori
properti
independ
contribut
therapeut
efficaci
futur
use
adjunct
immunomodul
infecti
diseas
requir
better
understand
microbi
pathogenesi
rel
need
immun
activ
versu
immun
modul
context
immun
respons
affect
individu
light
fact
certain
infecti
diseas
reflect
insuffici
respons
wherea
other
reflect
overli
exuber
respons
differ
type
intervent
like
requir
depend
immun
statu
patient
figur
damagerespons
framework
use
tool
consid
type
intervent
might
success
predict
requir
experiment
valid
translat
bedsid
clinic
paper
particular
interest
publish
within
annual
period
review
highlight
special
interest
outstand
interest
committe
new
direct
studi
antimicrobi
therapeut
immunomodul
treat
infecti
diseas
microbi
world
report
two
workshop
novel
antimicrobi
therapi
washington
dc
nation
academi
press
nation
academi
report
detail
potenti
modul
innat
acquir
immun
microbiota
enhanc
potenti
immunomodul
treatment
infecti
diseas
casadeval
pirofski
l
reapprais
humor
immun
base
mechan
antibodymedi
protect
intracellular
pathogen
adv
immunol
articl
deconstruct
older
view
antibodi
immun
limit
extracellular
organ
detail
newer
mechan
antibodi
action
includ
abil
function
proinflammatori
antiinflammatori
immunomodul
regul
cellular
immun
impactrsv
group
palivizumab
human
respiratori
syncyti
viru
monoclon
antibodi
reduc
hospit
respiratori
syncyti
viru
infect
highrisk
infant
pediatr
mejia
chavezbueno
rio
saavedralozano
j
fonseca
hatfield
j
kapur
p
gomez
jafri
hs
ramilo
antirespiratori
syncyti
viru
rsv
neutral
antibodi
decreas
lung
inflamm
airway
obstruct
airway
hyperrespons
murin
rsv
model
antimicrob
agent
chemoth
studi
evalu
effect
palivizumab
virolog
immunolog
paramet
lung
inflamm
mous
model
rsv
pneumonia
result
show
palivizumab
reduc
viral
load
lung
whether
given
h
rsv
infect
mab
administr
infect
associ
lower
level
inflammatori
mediat
less
lung
damag
import
implic
studi
time
mab
administr
key
determin
immunomodulatori
activ
